Agenus (NASDAQ:AGEN) Issues Quarterly Earnings Results

Agenus (NASDAQ:AGEN) released its quarterly earnings results on Monday. The biotechnology company reported $1.94 earnings per share for the quarter, missing analysts’ consensus estimates of $2.63 by ($0.69), Zacks reports. The firm had revenue of $30.24 million for the quarter, compared to analyst estimates of $80.39 million.

Agenus Stock Up 1.4%

Shares of AGEN stock opened at $4.27 on Wednesday. Agenus has a 12 month low of $1.38 and a 12 month high of $7.34. The firm has a market cap of $136.06 million, a PE ratio of -0.60 and a beta of 1.43. The stock has a 50 day moving average of $4.18 and a 200-day moving average of $4.50.

Hedge Funds Weigh In On Agenus

Several large investors have recently bought and sold shares of the stock. Invesco Ltd. bought a new stake in Agenus in the 1st quarter valued at $88,000. AQR Capital Management LLC lifted its stake in shares of Agenus by 3,080.3% in the first quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock valued at $664,000 after buying an additional 427,604 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Agenus in the first quarter valued at about $58,000. JPMorgan Chase & Co. grew its position in Agenus by 608.0% during the second quarter. JPMorgan Chase & Co. now owns 78,637 shares of the biotechnology company’s stock worth $359,000 after buying an additional 67,530 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in Agenus during the second quarter valued at about $1,976,000. 61.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

AGEN has been the topic of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Agenus in a research report on Wednesday, October 8th. Wall Street Zen lowered Agenus from a “buy” rating to a “hold” rating in a report on Sunday, August 17th. Zacks Research raised Agenus to a “hold” rating in a research note on Tuesday, August 12th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Agenus in a research report on Monday, October 20th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $14.50.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.